Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.
Badar T, Knutson K, Foran JM, Gangat N, Pavelko KD, Kaufmann SH, Litzow MR, Murthy HS, Cogen D, Ushman M, Arsana A, Al-Kali A, Alkhateeb HB, Tefferi A, Patnaik MM, Shah MV. Badar T, et al. Among authors: foran jm. Blood Adv. 2024 Nov 21:bloodadvances.2024014553. doi: 10.1182/bloodadvances.2024014553. Online ahead of print. Blood Adv. 2024. PMID: 39571168 No abstract available.
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan AM, Bewersdorf JP, Mendez L, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana Yi C, Osman AEG, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. Xie Z, et al. Blood. 2024 Nov 7;144(19):2033-2044. doi: 10.1182/blood.2024024756. Blood. 2024. PMID: 38996210 Free PMC article.
Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide.
Baranwal A, Langer KJ, Kharfan-Dabaja MA, Ayala E, Foran J, Murthy H, Roy V, Iqbal M, Palmer J, Sproat LZ, Chhabra S, Khera N, Durani U, Hefazi M, Mangaonkar A, Shah MV, Litzow MR, Hogan WJ, Alkhateeb HB. Baranwal A, et al. Transplant Cell Ther. 2024 Aug 16:S2666-6367(24)00589-X. doi: 10.1016/j.jtct.2024.08.009. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39154913
Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms.
Jabban Y, Yacout M, Baranwal A, He R, Viswanatha D, Greipp P, Jevremovic D, Bessonen K, Foran J, Palmer J, Saliba AN, Hefazi-Torghabeh M, Begna K, Hogan WJ, Mangaonkar A, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Jabban Y, et al. Leuk Lymphoma. 2024 Nov 6:1-10. doi: 10.1080/10428194.2024.2425048. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39504138
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein A, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT. DiNardo CD, et al. Among authors: foran jm. Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302. Blood Adv. 2024. PMID: 38640348 Free PMC article. Clinical Trial.
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Hoff FW, et al. Among authors: foran jm. Blood Adv. 2024 Oct 22;8(20):5297-5305. doi: 10.1182/bloodadvances.2024013685. Blood Adv. 2024. PMID: 39110987 Free PMC article.
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, Walter RB, Pettit K, Savona MR, Shah MV, Kremyanskaya M, Baer MR, Foran JM, Schiller G, Adès L, Heiblig M, Berthon C, Peterlin P, Rodríguez-Arbolí E, Salamero O, Patnaik MM, Papayannidis C, Grembecka J, Cierpicki T, Clegg B, Ray J, Linhares BM, Nie K, Mitra A, Ahsan JM, Tabachri M, Soifer HS, Corum D, Leoni M, Dale S, Fathi AT. Wang ES, et al. Among authors: foran jm. Lancet Oncol. 2024 Oct;25(10):1310-1324. doi: 10.1016/S1470-2045(24)00386-3. Lancet Oncol. 2024. PMID: 39362248 Clinical Trial.
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission.
Rahman ZA, Othman T, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. Rahman ZA, et al. Among authors: foran jm. Transplant Cell Ther. 2024 Dec;30(12):1197-1205. doi: 10.1016/j.jtct.2024.09.020. Epub 2024 Sep 26. Transplant Cell Ther. 2024. PMID: 39332807
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience.
Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A. Csizmar CM, et al. Among authors: foran jm. Haematologica. 2024 Nov 1;109(11):3785-3789. doi: 10.3324/haematol.2024.285359. Haematologica. 2024. PMID: 38899336 Free PMC article. No abstract available.
125 results